|
|
|
Amgen
Acquiring Alantos for $300M
|
|
|
| June
6, 2007--Amgen
is acquiring Alantos, a private company developing drugs
for the treatment of diabetes and inflammatory diseases,
for $300 million. Alantos' lead drug candidate, ALS
2-0426, is a DPP-IV inhibitor in clinical development for
the treatment of type II diabetes. Amgen
|
|
|
|
|
|
|
